Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/27035
Title: | Novel therapies in clinical use for the management of hyperlipidaemia |
Authors: | Mettananda, C. |
Keywords: | Novel therapies Hyperlipidaemia LDL Bempedoic acid PCSK9 inhibitors Inclisiran siMRNA |
Issue Date: | 2023 |
Publisher: | Sri Lanka College of Internal Medicine |
Citation: | Asian Journal of Internal Medicine.2023;2(2):35-38 |
Abstract: | Optimal control of low-density lipoprotein cholesterol (LDLc) is identified as a major target in reducing cardiovascular disease burden globally. However, existing lipid-lowering therapies have not been able to achieve LDLc targets even in developed countries. Therefore, novel therapies for the management of hyperlipidaemia are being trialled. Currently, there are three main groups of newer medicines; bempedoic acid, PCSK9 inhibitors and inclisiran, in addition to statins and ezetimibe in use for the management of hyperlipidaemia. This article aims to introduce these newer medicines and their clinical use in the treatment of hyperlipidaemia. |
Description: | Not Indexed |
URI: | http://repository.kln.ac.lk/handle/123456789/27035 |
ISSN: | 2827-7260 (Print) |
Appears in Collections: | Journal/Magazine Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
64d0796d85453.pdf | 470.95 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.